A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Recruiting now · Phase 3

Conditions studied: Extensive-Stage Small Cell Lung Cancer

In brief

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.

Key facts

Study ID

NCT06646276

Run by

Bristol-Myers Squibb

People needed

530

Starts

2025-02-25

Expected to finish

2031-09-05

Last updated by the study team

2026-07-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
• Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale.
• Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system

You may not qualify if…

• Participants have already received certain types of treatment for extensive stage small cell lung cancer
• Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where it is running

• Institutul Regional de Oncologie — Iași, Romania (enrolling)
• Sanford Fargo Medical Center — Fargo, North Dakota, United States (enrolling)
• Southern Cancer Center, PC — Daphne, Alabama, United States (enrolling)
• S.C. Centrul de Oncologie Euroclinic S.R.L. — Iași, Romania (enrolling)
• Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital — Marietta, Georgia, United States (enrolling)
• Illinois Cancer Care — Peoria, Illinois, United States (enrolling)
• Mid Florida Hematology and Oncology Center — Orange City, Florida, United States (enrolling)
• University of New Mexico Comprehensive Cancer Center — Albuquerque, New Mexico, United States (enrolling)
• Florida Cancer Specialists - North — St. Petersburg, Florida, United States (enrolling)
• Hospital Kuala Lumpur — Kuala Lumpur, Kuala Lumpur, Malaysia (enrolling)
• Florida Cancer Specialists - South — Fort Myers, Florida, United States (enrolling)
• Oncology Hematology Care — Cincinnati, Ohio, United States (enrolling)
• Sanford Cancer Center — Sioux Falls, South Dakota, United States (enrolling)
• SCRI Oncology Partners — Nashville, Tennessee, United States (enrolling)
• Texas Oncology - Central/South Texas — Austin, Texas, United States (enrolling)
• Texas Oncology - Northeast Texas — Tyler, Texas, United States (enrolling)
• Oncology & Hematology Associates of Southwest Virginia, Inc. — Roanoke, Virginia, United States (enrolling)
• Swedish Cancer Institute - Edmonds — Edmonds, Washington, United States (enrolling)
• Swedish Medical Center — Seattle, Washington, United States (enrolling)
• Duke Cancer Institute — Durham, North Carolina, United States (enrolling)
• Sanford Medical Center — Bismarck, North Dakota, United States (enrolling)
• Thoraxklinik-Heidelberg gGmbH — Heidelberg, Germany (enrolling)
• Local Institution - 0094 — Río Cuarto, Córdoba Province, Argentina
• Local Institution - 0080 — CABA, Buenos Aires F.D., Argentina
• Local Institution - 0100 — Buenos Aires, Buenos Aires F.D., Argentina

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.